Pathophysiology and treatment of idiopathic hypercalciuria

Current Opinion in Rheumatology

Volumn 10, Issue 4, 1998, Pages 373-388

  Bataille, Pierre ^a   Fardellone, Patrice ^a   Ghazali, Abder ^a   Cayrolle, Gisèle ^a   Hottelart, Carine ^a   Achard, Jean Michel ^a   Fournier, Albert ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; OXYGENASE; VITAMIN D RECEPTOR;

ALCOHOL CONSUMPTION; BONE ATROPHY; CALCIUM ABSORPTION; CALCIUM EXCRETION; CALCIUM INTAKE; CARBOHYDRATE INTAKE; CELL MEMBRANE; DIET THERAPY; DISEASE CLASSIFICATION; HUMAN; IDIOPATHIC HYPERCALCIURIA; INTESTINE ABSORPTION; KIDNEY TUBULE ABSORPTION; NUTRITION; PATHOPHYSIOLOGY; PHOSPHATE INTAKE; POTASSIUM INTAKE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; SODIUM INTAKE;

BONE DISEASES, METABOLIC; CALCIUM; CALCIUM METABOLISM DISORDERS; HUMANS;

EID: 0031666586     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199807000-00017     Document Type: Review

References (113)

1. Albright F, Henneman P, Benedict P, Forbes AP: Idiopathic hypercalciuria: a preliminary report. Proc B Soc Med London (Biol) 1953, 46:1077-1108.
2. Pak CYC, Britton F, Peterson R, et al.: Ambulatory evaluation of nephrolithiasis: classification, clinical presentation and diagnostic criteria. Am J Med 1980, 69:19-30.
3. Coe FL, Parks JH, Moore ES: Familial idiopathic hypercalciuria. N Engl J Med 1979, 300:337-340.
4. Favus MJ: Familial forms of hypercalciuria. J Urol 1989, 141:719-722.
5. Lemann JJ, Adams ND, Gray RW: Urinary calcium excretion in human beings. N Eng J Med 1979, 301:535-541.
6. Lemann JJ, Woraster EA, Gray RW: Hypercalciuria and stones. Am J Kidney Dis 1991, 17:386-390.
7. Golfarb S: Dietary factors in the pathogenesis and prophylaxis of nephrolithiasis. Kidney Int 1988, 34:544-555.
8. Bataille P, Achard JM, Fournier A, et al.: Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991, 39:1193-1205.
9. Lemann JJ, Worcester ER: Nephrolithiasis. In Textbook of Nephrology. Edited by Massry S, Glassock R. Baltimore: Williams & Wilkins; 1995, 1054-1078.
10. Hess R, Ackermann D, Essig M, Takkinen R, Jaeger P: Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake. J Clin Endocrinol Metab 1995, 80:1916-1921.
11. Allen LH, Oddoye EA, Margen S: Protein induced hypercalciuria, a longer term study. Am J Clin Nutr 1979, 32:741-749.
12. Walker BM, Linkswiller HM: Calcium retention in the adult human male is affected by protein intake. J Nutr 1972, 102:1297-1302.
13. Ulmann A, Aubert T, Bourdeau P: Effects of weight and glucose ingestion on urinary calcium and phosphate metabolism: implications for calcium urolithiasis. J Clin Endocrinol Metab 1982, 54:1063-8.
14. Lemann JJ, Pleuss JA, Gray RW, Hoffmann RG: Potassium administration reduces and potassium deprivation increases urinary calcium excretion in adults. Kidney Int 1991, 39:973-983.
15. Sebastian A, Hemandez RE, Portale AA, Colman J, Tassuno J, Morris RCJ: Dietary potassium influences kidney maintenance of serum phosphorus concentration. Kidney Int 1990, 37:1341-1347.
16. Breslau NA: Pathogenesis and management of hypercalciuric nephrolithiasis. Miner Electrol Metab 1994, 20:328-339.
17. Coe FL, Favus MJ, Asplin JR: Nephrolithiasis. In The kidney, vol 2. Edited by Brenner B. Philadelphia: WB Saunders, 1996, 1893-1935.
18. Frymoyer PA, Scheinman SJ, Dunham PP, Jones DB, Hueber P, Schroeder ET: X-linked recessive nephrolithiasis with renal failure. N Engl J Med 1991, 325:681-686.
19. Wrong OM, Norden AGW, Feest TG: Dent's disease: a familial proximal tubular syndrome with low-molecular weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. Q J Med 1994, 87:473-493.
20. Bolino A, Devoto M, Enia G, Zoccali C, Romeo G: A2 new form of X-linked hypophosphatemic ricketts with hypercalciuria (HDPR II) maps in the Xp11 region. Eur J Hum Genet 1993, 1:269-279.
21. Iragashi T, Hayakawa H, Shiraga H, et al.: Hypercalciuria and nephrolithiasis in patients with idiopathic low molecular weight proteinuria in Japan: is the disease identical to Dent's disease in UK? Nephron 1995, 69:242-7.
22. Lloyd SE, Pearce SHS, Fisher SE, et al.: A common molecular basis for three inherited kidney stone diseases. Nature 1996, 379:445-449. The first paper to report the link between three types of inherited hypercalciuric nephrolithiasis and defects in a gene encoding a chloride channel.
23. Scheinman SJ: X-linked hypercalciuric nephrolithiasis: clinical syndromes and chloride channel mutations. Kidney Int 1998, 53:3-7. Updates the recent understanding of the X-linked hypercalciuric nephrolithiasis associated with chloride channel mutations.
24. Fischer S, Van Bakel I, Lloyd S, Pearce S, Thakker R, Craig I: Cloning and characterization of CLCN5 the human kidney chloride channel gene implicated in Dent's disease (an X-linked hereditary nephrolithiasis). Genomics 1995, 29:598-606.
25. Vezzoli G, Zerbi S, Baragetti J, et al.: Nonacidotic proximal tubulopathy transmitted as autosomal dominant trait. Am J Kidney Dis 1997, 29:490-495.
26. Pollak MR, Brown EM, Chow YH: Mutations on the human Ca++ sensing receptor gene cause familial hypocalciuria hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993, 75:1297-1303.
27. Pearce SHS, Williamson C, Kifor O, et al.: A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium sensing receptor. N Eng J Med 1996, 335:1115-1122. This report gives information on a familial syndrome of hypocalcemia with hypercalciuria in relation to a mutation in the CaSR in the kidney. This description is very informative about the functional role of the CaSR in the kidney.
28. Breslau NA, Preminger M, Adams BV, Otey I, Pak CYC: Use of ketoconazole to probe the pathogenetic importance of 1,25-dihydroxyvitamin D in absorptive hypercalciuria. J Clin Endocrinol Metab 1992, 75:1446-1452.
29. Bataille P, Bouillon R, Fournier A: Increased plasma concentrations of total and free 1,25(OH)2D3 in calcium stone formers with idiopathic hypercalciuria, pathogenesis and treatment of nephrolithiasis. Contrib Nephrol 1986, 58:50-53.
30. Burckhardt P, Jaeger P: Secondary hyperparathyroidism in idiopathic renal hypercalciuna: fact or theory? J Clin Endocrinol Metab 1981, 53:550-551.
31. Levy FI, Adams-Huet B, Pak CYC: Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med 1995, 98:50-59.
32. Broadus AE, Insogna KL, Lang R, Ellison AF, Dreyer BE: Evidence for disordered control of 1,25 dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 1984, 311:73-80.
33. Monk RD, Bushinsky DA: Pathogenesis of idiopathic hypercalciuria. In Kidney Stones: Medical and Surgical Management. Philadelphia: Lippincott-Raven, 1996, 759-772. In this review of idiopathic hypercalciuria, the authors give some evidence for a link between human IH and the rat model of IH due to abnormal expression of the VDR.
34. Insogna KL, Broadus AE, Dreyer BE, Ellison AF, Gertner JM: Elevated production rate of 1,25 dihydroxy-vitamin D in patients with absorptive hypercalciuria. J Clin Endocrinol Metab 1985, 61:490-495.
35. Gray RW, Wilz DR, Caldas AE, Lemann JJ: The importance of phosphate in regulating plasma 1,25 (OH)2 vitamin D Levels in humans. J Clin Endocrinal Metab 1977, 45:299-306.
36. Shen FH, Baylink DJ, Nielsen RL, Sherrard DJ, Ivey JL, Haussler MR: Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria. J Lab Clin Med 1977, 90:955-962.
37. Tieder M, Modaï D, Shaked U, Samuel B: Idiopathic hypercalciuria and hereditary hypophosphotemic rickets: two phenotypical expressions of a common genetic defect. N Engl J Med 1987, 316:125-129.
38. Favus MJ, Mangelsdorf DJ, Tembe V, Coe BJ, Haussler MR: Evidence for in vivo upregulation of the intestinal vitamin D receptor during dietary calcium restriction in the rat. J Clin Invest 1988, 83:218-224.
39. Zerwekh JE, Yu XP, Breslau NA, Manolagas S, Pak CYC: Vitamin D receptor quantitation in human blood mononuclear cells in health and disease. Mol Cell Endocrinol 1993, 96:1-6.
40. Zerwekh J, Reed M, Pak C: Vitamin D receptor mRNA and protein concentration are normal in patients with absorptive hypercalciuria before and following 1,25-dihydroxyvitamin D3 mediated upregulation. In Urolithiasis. Edited by Pak CYC, Resnick MI, Preminger GM. Dallas: Millet, The Printer, 1996, 546-547.
41. Berlin T, Holmberg I, J B: Is 25-OH D3 of importance for development of hypercalciuria in renal stone formers? In Vitamin D. A Chemical, Biochemical and Clinical Update. Edited by Norman AW, Berlin: Walter de Gruyter, 1985.
42. Netenbolos JC, Jongen JM, Wim JF: Vitamin D status in urinary calcium stone formation. Arch Intern Med 1985, 145:681-684.
43. Heaney RP, Barger-Lux MJ, Chen TC, Holick MF: Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrin Metab 1997, 68:4111-4116. By measuring the molar efficiency ratio of calcitnol and calcidiol administration on the calcium absorption in healthy subjects, the authors demonstrate that physiologic concentrations of 25 (OH) vitamin D account for 18% of basal active calcium intestinal absorption.
44. Qaw F, Calverley MJ, Schroeder NJ, Makin HL, Jones G: In vivo metabolism of the vitamin D analog dihydrotachysterol: evidence for formation of 1-α-25 and 1-β-25 dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem 1993, 268:282-292.
45. Sakhaee K, Nicar MJ, Brater C, Pak CYC: Exaggerated natriuretic and calciuric responses to hydrochlorothiazide in renal hypercalciuria but not in absorptive hypercalciuria. J Clin Endocrinol Metab 1985, 61:825-829.
46. Sutton R, Walker V: Responses to hydrochlorothiazide and acetazolamide in patients with calcium stones: evidence suggesting a defect in renal tubular function. N Engl J Med 1980, 302:709-715.
47. Houillier P, Normand M, Froissart M, Blanchard A, Jungers P, Paillard M: Calciuric response to an acute acid load in healthy subjects and hypercalciuric calcium stone formers. Kidney Int 1996, 50:987-997. This elegant study demonstrates abnormal tubular handling of calcium in patients with IH and localizes this abnormality in the thick ascending limb of Henle's loop.
48. Tsuruoka S, Bushinsky DA, Schwartz G: Defective renal calcium reabsorption in genetic hypercalciuric rats. Kidney Int 1997, 51:1540-7.
49. Jaeger P, Lippuner K, Casez JP, Hess B, Ackermann D, Hug C: Low bone mass in idiopathic renal stone formers: magnitude and significance. J Bone Miner Res 1994, 9:1525-1532.
50. Melton LJ, Crowson CS, Khosla S, Wilson DM, O'Fallon WH: The fracture risk among patients with urolithiasis: a population basal cohort study. Kidney Int 1998, 53:459-64. Documents the actual fourfold increase risk for vertebral fractures in men and women with urolithiasis independent of corticoid and thiazide therapy.
51. Hosking DH, Erikson SB, Van den Berg CJ, Wilson DH, Smith LH: The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 1983, 130:1115-20.
52. Fournier A, Ghazali A, Bataille P, et al.: Bone involvement in idiopathic calcium stone formers. In Kidney Stones: Medical and Surgical Management. Edited by Coe FL, Favus MJ, Preminger G, Philadelphia: Lippincott-Raven, 1996, 921-938.
53. Lawoyin S, Sismilich S, Browne R, Pak CYC: Bone mineral content in patients with calcium urolithiasis. Metabolism 1979, 28:1250-1254.
54. Lindergard B, Colleen S, Mansson W, Rademark C, Rogland B: Calcium loading test and bone disease in patients with urolithiasis. Proc EDTA 1983, 20:460-465.
55. Bordier P, Ryckewart A, Gueris J, Rasmussen H: On the pathogenesis of so called idiopathic hypercalciuria. Am J Med 1977, 63:398-409.
56. De Vernejoul MC, Hioco D, Villaumey J, Chanzy MO, Voisin MC, Canalia AM: Etude histomorphométrique osseuse au cours de l'hypercalciurie idiopathique. Revue Rhum 1981, 48:389-395.
57. Malluche HH, Tschoepe W, Ritz E, Meyer-Sabellek W, Massry SG: Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 1980, 50:654-658.
58. Steiniche T, Morsekilde L, Christensen MS, Melsen F: A histomorphometric determination of iliac bone remodeling in patients with recurrent renal stone formation and idiopathic hypercalciuria. Acta Pathol Microbiol Immunol Scand 1989, 97:309-316.
59. Bataille P, Hardy P, Marie A, et al.: Decreased bone formation explains reduced bone density. J Bone Miner Res 1995, 10:S401.
60. Da Silva AMM, Dos Rei LH, Pereira RC: Bone histomorphometric and bone mineral content in idiopathic hypercalciuria [abstract]. XIIth International Congress of Nephrology, Jerusalem, Israel 1993: 620.
61. Heilberg JP, Martini LA, Szynfeld VL, et al.: Bone disease in calcium stone forming patients. Clin Nephrol 1994, 42:175-182.
62. Misael AM, Pereira RC, dos Reis LM, Noronha IL, Jorgetti V: Bone involvement in idiopathic hypercalciuria. In Renal Stone Disease. Edited by Jungers P, Daudon M. Paris: Elsevier, 1997, 173-174.
63. Bernat M, Renier JC, Rebel A, Jallel P: Hypercalciurie idiopathique: etude de corrélative du tissu osseux et des explorations phosphocalciques. Revue Rhum 1979, 46:7-18.
64. Zerwekh JE, Sakhaee K, Breslau NA, Gottschalk F, Pak CY: Impaired bone formation in male idiopathic osteoporosis: further reduction in the presence of concomitant hypercalciuria. Osteoporos Int 1992, 2:128-134.
65. Bataille P, Marie A, Ghazali A, et al.: Histological and biochemical study of bone turn over in calcium stone formers with fasting hypercalciuria and osteopenia. In Renal Stone Disease. Edited by Jungers P, Daudon M. Paris: Elsevier, 1997, 190. The authors describe the main relationships observed between histomorphometric abnormalities and protein diet and calciotropic hormones in patients with IH and low bone mass.
66. Baylink D, Werfed J, Stanferr M: Formation, mineralization and resorption of bone in hypophasphatemic rats. J Clin Invest 1971, 50:2519-2530.
67. Messa P, Mioni G, Montanaro D: About primitive osseous origin of the so-called idiopathic hypercalciuria, In Pathogenesis and treatment of nephrolithiasis, vol. 58. Edited by Linari C, Marangella C. Basel: Karger, 1986, 106-110.
68. Transchieri A, Rovera F, Nespoli R, Ostini F, Curro A, Zanetti G: Urinary excretion of pyridinium cross links in idiopathic renal calcium stone formers. In Renal Stone Disease. Edited by Jungers P, Daudon M. Paris: Elsevier; 1997:183-184.
69. Silva JAH, Pieroni FB, Milagres G, Pardini VC: Total deoxypyridinoline and bone density in nephrolithiasis. In Renal Stone Disease. Edited by Jungers P, Daudon M. Paris: Elsevier, 1997, 191-192.
70. Fuss M, Pepersack T, Van Geel J: Involvement of low calcium diet in the reduced bone mineral content of idiopathic renal stone formers. Calcif Tissue Int 1990, 46:9-13.
71. Hess B, Casez J, Takkinen D, Ackerman D, Jaeger P: Relative hypoparathyroidism and calcitriol up regulation in hypercalciuric calcium renal stone formers: impact of nutrition. Am J Nephrol 1993, 13:18-26.
72. Bataille P, Marie A, Ghazali A, et al.: Role of protein diet, parathyroid hormone and calcitriol in the bone turnover changes of calcium stone formers (CSF) with fasting hypercalciuria. In Renal Stone Disease. Edited by Jungers P, Daudon M. Paris: Elsevier; 1997, 179-180.
73. Pietschmann F, Breslau NA, Pak CYC: Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992, 97:699-705.
74. Pacifici R, Rothstein M, Rifast K, et al.: Increased monocyte interleukin I activity and decreased vertebral bone mineral density in patients with fasting idiopathic hypercalciuria. J Clin Endocrinol Metab 1990, 71:138-145.
75. Weisinger JR, Alonzo E, Bellorin Font E, et al.: Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 1996, 49:244-250. An interesting view of the role of disturbed cytokine production and bone disease in patients with IH.
76. Ghazali A, Fuentes V, Desaint C, et al.: Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 1997, 82:32-38. New information on the role of cytokines and bone disease in patients with IH. A protective role of granulocyte-macrophage colony-stimulating factor is proposed, and the deleterious effects on bone due to excess production of interleukin-1 and -6, as well as tumor necrosis factor-α, are described.
77. Ghazali A, Bataille P, Fuentes V, et al.: Evidence for spontaneous activation of peripheral blood monocyte in calcium stone formers with idiopathic hypercalciuria by ex vivo over expression of CD14. In Renal Stone Disease. Edited by Jungers P, Daudon M. Paris: Elsevier; 1997, 175-176.
78. Coe FL, Favus MJ, Crockett T, et al.: Effects of low calcium diet on urine calcium excretion, parathyroid function and serum 1,25 (OH)2 D3 levels in patient with idiopathic hypercalciuria and in normal subjects. Am J Med 1982, 72:25-31.
79. Baggio B, Gambaro G, Marchini F, Cicerello E, Borsatti A: Raised transmembrane oxalate flux in red blood cells in idiopathic oxalate lithiasis. Lancet 1984, 2:12-13.
80. Gambaro G, Vincenti M, Marchini F, D'Angelo A, Baggio B: Abnormal urate transport in erythrocytes of idiopathic calcium nephrolithiasis. Clin Sci 1993, 85:41-44.
81. Baggio B, Gambaro G, Marchini F, et al.: Abnormal erythrocyte and renal frusemide sensitive sodium transport in idiopathic calcium nephrolithiasis. Clin Sci 1994, 86:239-243.
82. Bianchi G, Vezzoli G, Cusi D, et al.: Abnormal red cell calcium pump in patients with idiopathic hypercalciuria. N Eng J Med 1988, 319:897-901.
83. Simon DB, Lifton RP: Ion transporter mutations in Gitelman's and Bartter's syndromes. Curr Opin Nephrol Hypertens 1998, 7:43-47.
84. Baggio B, Gambaro G, Zambon S, et al.: Anomalous phospnolipid in 6 polyunsaturated fatty acid composition in idiopathic calcium nephrolithiasis. J Am Soc Nephrol 1996, 7:613-620. This very interesting study provides new concepts in the pathogenesis of IH. A theory is put forward to explain abnormal ion transport activities, prostaglandin production, tubular dysfunction, and IH at the light of a generalized abnormality of membrane lipid content.
85. Henriquez La Roche C, Rodriguez Iturbe B, Parra G: Increased urinary excretion of prostaglandin E2 in patients with idiopathic hypercalciuria is a primary phenomenon. Clin Sci 1992, 83:75-80.
86. Bataille P, Fournier A, Boudaillez B, Westeel PF, Achard JM, Bouillon R: Idiopathic hypercalciuria: a proposal for a new cascade. In Nephrology, Vol. II. Edited by Hatano M. Tokyo: Springer Verlag, 1991, 1028-42.
87. Kurokawa K: Calcium regulating hormones and the kidney. Kidney Int 1987, 32:760-771.
88. Buck AC, Addis R, Bradoo A: Evening primrose oil and fish oil in the treatment of idiopathic recurrent urolithiasis: a double blind, placebo controlled study. In Renal Stone Disease. Edited by Junger P, Daudon M. Paris: Elsevier, 1997, 206.
89. Bushinsky D, Favus MJ: Mechanism of hypercalciuria in genetic hypercalciuric rats. J Clin Invest 1988, 82:1585-1591.
90. Xiao-Quiang L, Tembe V, Horwitz GM, Bushinsky DA, Favus MJ: Increased intestinal vitamin D receptor in genetic hypercalciuric rats: a cause of intestinal calcium absorption. J Clin Invest 1993, 91:661-667.
91. Krieger NS, Stathopoulos VM, Bushinsky DA: Increased sensitivity to 1,25 (OH)2 D3 in bone from genetic hypercalciuric rats. Am J Physiol 1996, 271:C130-C135.
92. Zerwekh JE, Hughes MR, Reed BY, et al.: Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria. J Clin Endocrinol Metab 1995, 80:2960-2965.
93. Reed BY, Heller HJ, Lemke M, et al.: Linkage analysis in absorptive hypercalciuria: lack of linkage to the vitamin D receptor or 1,25 (OH)2 D3 1 alpha hydroxylase loci. In Urolithiasis. Edited by Pak C, Rescnick M, Preminger G. Dallas: Millet, The Printer; 1996, 540-542.
94. Scott P, Oiumet D, Proulx Y, et al.: The 1α hydroxylase locus is not linked to calcium stone formation or calciuric phenotypes in French-Canadian families. J Am Soc Nephrol 1998, 9:425-432.
95. Yang T, Hassan S, Huang YG, Smart AM, Briggs JP, Schnermann JB: Expression of PTH/PTH rP receptor and Ca++ sensing receptor mRNAs along the rat nephron. Am J Physiol 1997, 272:F751-F758.
96. Hebert SC: Extra cellular calcium sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996, 5:45-53. The author focuses on recent data concerning the CaSR in the kidney and its role in calcium and magnesium tubular handling.
97. Wang W, Lu M, Balazy M, Hebert SC: Phospholipase A2 is involved in mediating the effect of extracellular Ca++ on apical K+ channels in rat TAL. Am J Physiol 1997, 273:F421-F429.
98. Filipponi P, Mannarelli C, Pacifci R: Evidence for a prostaglandin-mediated bone resorptive mechanism in subjects with fasting hypercalciuria. Calcif Tissue Int 1988, 43:61-66.
99. Calo L, Cantaro S, Marchini F, et al.: Is hydrochlorothiazide-induced hypocalciuria due to inhibition of prostaglandin E2 synthesis? Clin Sci 1990, 78:321-325.
100. Bonvalet JP, Pradelles P, Farman N: Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 1987, 253:F377-F387.
101. Kaji DM, Chase HS, Eng JP, Diaz J: Prostaglandin E2 inhibits Na-K-2Cl cotransport in medullary thick ascending limb cells. Am J Physiol 1996, 271:C354-C361.
102. Pacifici R: Idiopathic hypercalciuria and osteoporosis: distinct clinical manifestations of increased cytokine induced bone resorption? J Clin Endocrinol Met 1997, 82:29-31. This updated editorial gives an overview of the potential role of cytokines in patients with osteoporosis and IH.
103. Bataille P, Charransol G, Fournier A: Effect of calcium restriction on renal excretion of oxalate and their probability of forming some in the various pathophysiological groups of calcium stone-formers. J Urol 1983, 130:218-223.
104. Curhan GC, Willet WC, Rimm EB, Stamper MJ: A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Eng J Med 1993, 328:833-838.
105. Lemann JJ, Pleuss JA, Worcester EM, Hoffmann RG: Urinary oxalate increases with body size and decreases with dietary calcium intake among healthy adults. Kidney Int 1996, 49:300-308. This paper shows that the optimal calcium intake to prevent calcium stone and hypercalciuria is around 800 mg/d.
106. Bataille P, Pruna A, Hottelart C, et al.: Lithiase calcique idiopathique: correction des facteurs de risque métaboliques; bases physiopathologiques. Presse Médicale (Paris) 1998, 27:218-224.
107. Pruna A, Bataille P, Ghazali A, et al.: Lithiase calcique idiopathique: la cure de diurse. Presse Médicale (Paris) 1998, 27:225-229.
108. Achard JM, Bataille P, Hottelart C, et al.: Lithiase calcique idiopathique: guide pratique des mesures à prendre pour la surveillance et le traitement. Presse Médicale (Paris) 1998, 27:230-237.
109. Van Den Berg CY, Kumar R, Wilson DM, Heath H, Smith LW: Orthophosphates therapy decreases urinary calcium excretion and serum 1,25-dihydroxyvitamin D concentrations in idiopathic hypercalciuria. J Clin Endocrinol Metab 1980, 51:998-1001.
110. Insogna KL, Ellison AS, Burtis WG, Sartori L, Lang RL, Broadus AE: Trichlormethiazide and oral phosphate therapy in patients with absorptive hypercalciuria. J Urol 1989, 141:269-274.
111. Ettinger B, Citron J, Livermore B, Dolman L: Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988, 139:679-684.
112. Coe FL, Parks JH, Bushinsky DA, Langman CG, Favus MJ: Chlorthalidone promotes mineral retention in idiopathic hypercalciuria. Kidney Int 1988, 33:1140-1146.
113. Jones G, Nguyen T, Sambrook PN, Eisman IA: Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 1995, 10:106-111.